Omalizumab treatment in asthma-COPD overlap syndrome

Tat T. S., ÇİLLİ A.

JOURNAL OF ASTHMA, vol.53, no.10, pp.1048-1050, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 53 Issue: 10
  • Publication Date: 2016
  • Doi Number: 10.1080/02770903.2016.1178281
  • Journal Name: JOURNAL OF ASTHMA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1048-1050
  • Keywords: ACOS, omalizumab, LONG-TERM CONTROL
  • Akdeniz University Affiliated: Yes

Abstract

Introduction: Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a poorly understood disease with an increasing morbidity and mortality. Currently, the most effective treatment for ACOS is unknown and omalizumab for ACOS has not yet been reported. Methods: We report our experience with anti-IgE, omalizumab treatment on 3 patients with ACOS as a retrospective case study. Results: After 1 year of omalizumab treatment, patients experienced significantly lower rates of asthma exacerbation and hospitalization and better asthma control test results. Conclusion: Our study shows that omalizumab may be an effective and safe therapy for patients with ACOS. However larger randomized trials are needed.